Geoffrey Ira Shapiro MD PhD

PubMed

• A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.
  Filipa Lynce, Noah Graham, Bose S Kochupurakkal, Huy Nguyen, Brittany Bychkovsky
  Clinical Cancer Research. 2026-02-04
• Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.
  Sara A Walton, Justin J Kim, Francesco Paoloni, Jean W Liew, Danielle Haradon
  JCO Precision Oncology. 2025-12-01
• BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer via Induction of miR-34a-5p.
  Renyan Liu, Xin Wang, Timothy B Branigan, Daryl Griffin, Caoibhne McSweeney
  Clinical Cancer Research. 2025-12-01

Journal Articles

• KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors  
  David S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine
• Institutional Implementation of Clinical Tumor Profiling on an Unselected Cancer Population  
  Khanh Do, Lauren L Ritterhouse, William C Hahn, Geoffrey I Shapiro, Barrett J Rollins, Neal I Lindeman, Alanna Church, Geoffrey R Oxnard, Bruce E Johnson, Frank C Kuo,..., The Journal of Clinical Investigation
• Clinical development of the CDK4/6 inhibitors abemaciclib and ribociclib in breast cancer  
  Barroso-Sousa, Shapiro GI and Tolaney S.M., Breast Care, 1/1/2016

Books/Book Chapters

• PARP inhibitors for cancer therapy. 
  Chapter: Disruption of DNA repair by cell cycle and transcriptional CDK inhibition. 
  Page 413 - 430Cornell L, Johnson N, Shapiro GIEditors: NJ Curtin and RA Sharma.Humana Press2015

Abstracts/Posters

• GSK525762, a selective bromodomain (BRD) and extra termina protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with...
  O’Dwyer PJ, Piha-Paul S, French C, Harward S, Ferron-Brady G, Wu Y, Barbash O, Wyce A, Annan M, Horner T, Parr NJ, Prinjha RK, Carpenter C, Shapiro G, Dhar A, Hann C, Proc Amer Assoc Cancer Res, 1/1/2016
• Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus.
  George S, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Wagner AJ, Merriam P, Morgan JA, Rodig SJ, Hodi SF, Shapiro G, Demetri GD, J Clin Oncol, 1/1/2016
• In vivo synergism between PARP inhibitor olaparib and HSP90 ihibitor AT13387 in high-grade serous ovarian cancer patient-derived xenografts.
  Konstantinopoulos P, Palakurthi S, Zeng Q, Zhou S, Liu JF, Ivanova E, Paweletz C, Kommajosyula N, D’Andrea AD, Shapiro G, Matulonis UA, J Clin Oncol, 1/1/2016

Lectures

• Developmental Therapeutics and Tumor Biology (Nonimmuno) 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
• Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Other

• Small molecule inhibitors of cyclin-dependent kinases. In: M.V. Blagosklonny, editor. Cell Cycle Checkpoints and Cancer. 
  Shapiro GI, Landes Bioscience
  Georgetown, TX - 1/1/2001
• Thesis: Influenza virus gene expression: viral RNA replication in vivo and in vitro. 
  Shapiro GI, Weill-Cornell Graduate School of Medical Sciences,
  Cornell University - 1/1/1987